Acalabrutinib (CALQUENCE)
B-cell malignancies (e.g., CLL, MCL, SLL)
Approved/CommercialActive
Key Facts
Indication
B-cell malignancies (e.g., CLL, MCL, SLL)
Phase
Approved/Commercial
Status
Active
Company
About Acerta Pharma
Acerta Pharma, founded in 2012 and fully acquired by AstraZeneca in 2021, is a biotechnology company focused exclusively on haematology. It operates as AstraZeneca's dedicated European R&D hub for blood cancers, utilizing a proprietary covalent binding technology platform to discover and develop targeted small molecule therapies. The company's strategy is centered on addressing high unmet needs in over 130 types of blood cancers through innovative clinical strategies, including combination therapies. Its pipeline and research efforts are deeply integrated with AstraZeneca's broader oncology portfolio and resources.
View full company profile